Overview
Competes with alpha-MSH for binding to MC1-R receptors on melanocytes, reducing tyrosinase activity.
Proposed mechanism
Decapeptide-12 is a tyrosinase inhibitor that acts as an alpha-MSH antagonist, reducing melanogenesis at the receptor level.
What the evidence supports
Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Graded Animal
Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
Decapeptide-12 in pigmentation
· DOI:10.1111/j.1468-2494.2009.00528.x · 2009
- [2]
Peptide depigmenting agents
· DOI:10.1111/jocd.12197 · 2015
- [3]
Decapeptide-12 in pigmentation (2009)
· · 0
- [4]
Peptide depigmenting agents (2015)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.